RAP1A and prostate carcinoma: The same strategy of targeting protein geranylgeranylation slows tumor development in a murine model of prostate cancer metastasis possibly through reduction in Rap1A geranylgeranylation [403] and reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis [404].